|
|
|
| Antibacterial activity of polymyxin B in combination with several antimicrobial agents against carbapenem-resistant Klebsiella pneumoniae in vitro |
| WU Zhenghai1, LIU Haiyang1, CHEN Huale2, DUAN Darong3, ZHOU Tieli1. |
| 1.Laboratory Medicine Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015; 2.Laboratory Medicine Center, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325027; 3.Laboratory Medicine Center, the First People’s Hospital of Taizhou, Taizhou, 318020 |
|
| Cite this article: |
|
WU Zhenghai,LIU Haiyang,CHEN Huale, et al. Antibacterial activity of polymyxin B in combination with several antimicrobial agents against carbapenem-resistant Klebsiella pneumoniae in vitro[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2017, 47(12): 898-901.
|
|
|
|
Abstract Objective: To evaluate the combined inhibitory effect of polymyxin B with meropenem and rifampicin respectively against carbapenem-resistant Klebsiella pneumoniae (CRKP) strains in vitro. Methods: Combined inhibitory effect of polymyxin B and meropenem, polymyxin B and rifampicin in vitro was assayed by detecting the minimum inhibitory concentration and calculating the fractional inhibitory concentration index for 20 CRKP strains with the checkerboard dilution method. Results: Combined polymyxin B and meropenem showed 55% synergic effect, 45% additive effect, no indifferent and antagonistic effect on CRKP strains. Combined polymyxin B and rifampicin displayed 65% synergic effect, 35% additive effect, no indifferent and antagonistic effect on CRKP strains. Conclusion: Combined polymyxin B and meropenem, combined polymyxin B and rifampicin show a combined synergic and additive inhibitory on CRKP strain in vitro.
|
|
Received: 05 June 2017
|
| |
|
|
|
[1] 曹慧玲, 舒钊彻, 杨琳, 等. 亚胺培南与舒巴坦联合应用对多重耐药肺炎克雷伯菌的体外试验研究[J]. 实用医学杂志, 2016, 32(3): 475-478.
[2] LY N S, BULITTA J B, RAO G G, et al. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance[J]. J Antimicrob Chemother, 2015, 70(5): 1434-1442.
[3] National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement[S]. M100-S24, CLSI, 2014.
[4] 沈绍清, 任浩洋, 蔡芸. 多黏菌素联合用药研究进展[J]. 中国抗生素杂志, 2016, 41(3): 166-172.
[5] 胡付品, 朱德妹, 汪复, 等. 2015年CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2016, 16(6): 685-694.
[6] PITOUT J D , NORDMANN P, POIREL L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance[J]. Antimicrob Agents Chemother, 2015, 59(10): 5873-5884.
[7] BRATU S, TOLANEY P, KARUMUDI U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents[J]. J Antimicrob Chemother, 2005, 56(1): 128-132.
[8] ELEMAM A, RAHIMIAN J, DOYMAZ M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae[J]. J Clin Microbiol, 2010, 48(10): 3558-3562.
[9] TASCINI C, TAGLIAFERRI E, GIANI T, et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae[J]. Antimicrob Agents Chemother, 2013, 57(8): 3990-3993.
[10] QURESHI Z A, PATERSON D L, POTOSKI B A, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens[J]. Antimicrob Agents Chemother, 2012, 56(4): 2108-2113.
[11] WAREHAM D W, BEAN D C. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases[J]. Ann Clin Microbiol Antimicrob, 2006, 5(1): 1-5.
[12] 杨德青, 倪文涛, 王睿, 等. 多黏菌素耐药革兰阴性菌研究的文献计量分析[J]. 中国临床药理学杂志, 2016, 32(17): 1617-1620. |
|
|
|
